2.07
price down icon0.96%   -0.02
 
loading
Immunitybio Inc stock is traded at $2.07, with a volume of 6.51M. It is down -0.96% in the last 24 hours and down -20.38% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.09
Open:
$2.095
24h Volume:
6.51M
Relative Volume:
0.95
Market Cap:
$2.24B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.134
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-18.50%
1M Performance:
-20.38%
6M Performance:
-62.84%
1Y Performance:
-74.32%
1-Day Range:
Value
$2.03
$2.2099
1-Week Range:
Value
$1.83
$2.425
52-Week Range:
Value
$1.83
$9.16

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
680
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.07 2.24B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
May 09, 2025

Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 08, 2025
pulisher
May 06, 2025

ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A - GuruFocus

May 06, 2025
pulisher
May 05, 2025

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive By Stocktwits - Investing.com India

May 05, 2025
pulisher
May 05, 2025

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha

May 05, 2025
pulisher
May 05, 2025

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive - MSN

May 05, 2025
pulisher
May 05, 2025

ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal

May 05, 2025
pulisher
May 05, 2025

Unity lays off ‘all’ workers; Novo to get FDA decision on oral Wegovy this year - Endpoints News

May 05, 2025
pulisher
May 05, 2025

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga

May 05, 2025
pulisher
May 05, 2025

ImmunityBio stock sinks after FDA issues RTF letter By Investing.com - Investing.com Nigeria

May 05, 2025
pulisher
May 05, 2025

ImmunityBio stock sinks after FDA issues RTF letter - Investing.com Australia

May 05, 2025
pulisher
May 05, 2025

ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre - GuruFocus

May 05, 2025
pulisher
May 05, 2025

ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Business Wire

May 05, 2025
pulisher
May 01, 2025

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting - The Globe and Mail

Apr 30, 2025
pulisher
Apr 29, 2025

Wainwright maintains $8 target on ImmunityBio shares post-AUA By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

Wainwright maintains $8 target on ImmunityBio shares post-AUA - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of ImmunityBio, Inc.(IBRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 29, 2025

IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 29, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha

Apr 29, 2025
pulisher
Apr 28, 2025

ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

IBRX Study Reveals Promising Results for Non-Muscle Invasive Bla - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i - StreetInsider

Apr 28, 2025
pulisher
Apr 27, 2025

SHAREHOLDER ALERT: Potential Recovery for ImmunityBio, Inc. (IBRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC - OncLive

Apr 27, 2025
pulisher
Apr 21, 2025

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace

Apr 21, 2025
pulisher
Apr 17, 2025

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey

Apr 17, 2025
pulisher
Apr 16, 2025

Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey

Apr 16, 2025
pulisher
Apr 15, 2025

ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio Completes FDA License Application Submissions - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Is ImmunityBio Stock Heading Upwards? - timothysykes.com

Apr 14, 2025
pulisher
Apr 10, 2025

ImmunityBio raises $75 million in direct offering - The Pharma Letter

Apr 10, 2025
pulisher
Apr 09, 2025

ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot

Apr 09, 2025
pulisher
Apr 09, 2025

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025
pulisher
Apr 09, 2025

Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN

Apr 09, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Cap:     |  Volume (24h):